Orthros Medical

What Orthros Medical does

Orthros Medical is a Dutch privately held biotech company, founded in 2017 as a spin-off of the University of Twente, that develops VHH (Variable Domain of Heavy-chain only antibodies) based therapeutics and diagnostics for the treatment of osteoarthritis in animals and humans. Its core technology leverages single-chain antibody fragments derived from llama heavy-chain-only antibodies, which are approximately 10x smaller than conventional human antibodies, exhibit low immunogenicity, retain full binding capacity, and can be manufactured in yeast systems. The company's lead pipeline consists of Disease Modifying Osteoarthritic Drugs (DMOADs) — VHH candidates targeting inflammation and cartilage catabolism enzymes — formulated as slow-release gels for intra-articular injection into osteoarthritic joints, with the goal of providing localized pain relief and disease modification.

Orthros pursues a partnership-driven, asset-light commercial model. In March 2022 it signed a global exclusive licensing agreement with Animalcare Group for two preclinical canine osteoarthritis VHH candidates, generating a €500,000 upfront payment with potential development, regulatory, and commercial milestones up to €11 million plus single-digit royalties on net sales. The company additionally offers contract manufacturing services for GMP-grade VHH production to other animal health businesses. Its customer segmentation is vertical-led: primary focus is veterinary pharmaceutical companies (initial canine and equine indications), with the human osteoarthritis market positioned as a longer-term expansion vector (planned human clinical trials around 2026).

The company is headquartered at the Green East Innovation Centre in Raalte, Netherlands, with plans to relocate to the University of Twente campus in Enschede. It operates with a team of approximately six people scaling to ten in 2023 and is led by CEO Robert Jan Lamers (15+ years of biotech BD experience) and CSO Marcel Karperien (University of Twente professor and serial biotech founder). Funding to date has come from Dutch institutional sources — ReumaNederland, RVO, and Oost NL — together with the Animalcare upfront payment. The company remains pre-revenue, with all disclosed candidates in preclinical development.

Name

Orthros Medical

Legal name

Orthros Medical

Website

https://orthros-medical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Orthros Medical is a Dutch preclinical biotech developing VHH-based therapeutics and diagnostics for osteoarthritis in animals and humans, licensing candidates to animal health partners and offering GMP-grade VHH contract manufacturing.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

akta.pro secondary industries

Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics (HLAMANAB), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• VHH antibody therapeutics
• Llama single-domain antibodies
• Osteoarthritis biologic drugs
• Veterinary biotech therapeutics
• Contract biomanufacturing services

Headquarters

HQ city

Raalte

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Through partnerships like Animalcare, receives upfront payments (€500,000), development, regulatory and commercial milestone payments (up to €11M total), and single digit royalties on net sales of licensed products.
2. Contract Manufacturing (GMP-grade VHH): Offers contract manufacturing services for GMP-grade VHH production on behalf of animal health businesses interested in using antibodies for other indications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Orthros Medical develops VHH (Variable Domain of Heavy-chain only antibodies) based therapeutics and diagnostics for animal and human health, focused on osteoarthritis. The company engineers single-chain antibody fragments derived from llamas into intra-articular injection therapies formulated as slow-release gels for localized pain relief and disease modification. It also offers contract manufacturing of GMP-grade VHH antibodies for partner companies.

Product overview

Orthros Medical is a Dutch biotech company developing a portfolio of VHH-based therapeutics and diagnostics for animal and human health. The core offerings center on Disease Modifying Osteoarthritic Drugs (DMOADs) based on single-chain llama antibodies, which the company combines with intra-articular injection therapies formulated in controlled release systems. The product pipeline includes VHH-based therapeutics targeting inflammation and pain for osteoarthritis treatment, with the first canine osteoarthritis candidates (licensed to Animalcare Group) progressing through preclinical development and plans for human Phase I trials. Additionally, the company offers contract manufacturing services for GMP-grade VHH production.

Differentiator

Problem solved

Functional benefit

Products and services

• VHH-based Osteoarthritis Therapeutics (Canine OA Candidates) Two preclinical VHH-based therapeutic candidates licensed exclusively to Animalcare Group for the treatment of canine osteoarthritis, developed as mono and combination therapy for local application in osteoarthritic joints to provide pain relief and disease modification. Licensed to animal health companies through global exclusive licenses with milestone and royalty terms.
• VHH-based Disease Modifying Osteoarthritic Drug (DMOAD) Pipeline Portfolio of VHH-based drug candidates targeting various aspects of inflammation and enzymes involved in cartilage catabolism to provide disease-modifying treatment of osteoarthritis in humans. Candidates are formulated for local intra-articular delivery with sustained release to increase precision and reduce side effects.
• VHH-based Diagnostics Diagnostic products leveraging the unique properties of VHH (single-chain llama-derived antibody fragments) for disease detection in animal and human health applications.
• GMP-grade VHH Contract Manufacturing Services Contract manufacturing services producing VHH antibodies at GMP-grade for animal health businesses interested in using the antibodies for indications outside of Orthros Medical's own pipeline. Leverages the company's proprietary yeast-based manufacturing platform for scalable, lower-cost production of VHH antibodies.

Quantifiable outcome

• VHH antibodies are ~10x smaller than human antibodies
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Animalcare GroupcoreStrategic or Co-development Partner · 24 March 2022Animalcare Group secured a global exclusive license from Orthros Medical for two preclinical VHH candidates addressing canine osteoarthritis. Additionally, an R&D agreement aims to add further projects. Upfront payments of €500,000 with milestone payments up to €11M plus single digit royalties on net sales.
• University of TwentecoreStrategic or Co-development PartnerOrthros Medical is a spin-off of the University of Twente. Close collaboration in research and development has resulted in joint patents and product candidates. The company is located in the region and plans to relocate to the UT Campus in Enschede.
• QVQcoreTechnology or IntegrationQVQ is both a minority shareholder and a trusted partner in VHH selection and development. Provides expertise in antibody selection and development processes.
• EFRO ConsortiumminorStrategic or Co-development PartnerEFRO Consortium 'Development and production of therapeutic antibodies for regenerative medicine' includes partners: QVQ, IAMfluidics, University of Twente, and Orthros Medical. EU-funded development program.
• Green EastminorOthersLocated in the Green East Innovation Centre, providing access to innovation ecosystem and facilities for the company.
• Zwolle IncubatorminorOthersPartner incubator providing startup support and ecosystem access.
• NWO (Netherlands Organisation for Scientific Research)minorOthersNational research funding organization supporting scientific research in the Netherlands.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Ablynx (Sanofi): Ablynx, now part of Sanofi, pioneered VHH/nanobody drug development and brought the first VHH therapy (caplacizumab) to market. As a Sanofi-owned franchise, it represents the incumbent path for VHH therapeutics and a potential acquirer/partner benchmark for Orthros.
• Elanco Animal Health: Elanco is a major global animal health company with established osteoarthritis and pain franchises in companion animals. It is a comparable animal-health commercialization counterpart and a potential alternative partner for future VHH candidates.
• Bio-Rad Laboratories: Bio-Rad is a major life sciences and diagnostics company that supplies antibody-based reagents and diagnostic platforms. It is a broad incumbent relevant to Orthros's secondary VHH-diagnostics ambitions and a potential channel/distribution counterpart.
• Zoetis: Zoetis is the largest global animal health company, with a strong osteoarthritis franchise in dogs and horses (including monoclonal antibody therapies like bedinvetmab/Librela). It is the dominant incumbent in the canine OA market where Orthros's Animalcare-licensed candidates will compete.

Direct peers

• Argenx: Argenx is the leading clinical and commercial VHH/nanobody company, with FDA-approved VHH drugs and a broad immunology pipeline. It is the most direct technological peer to Orthros and effectively defines the VHH competitive landscape Orthros is operating in.
• Animalcare Group: Animalcare is Orthros's exclusive licensee for canine OA VHHs and is itself a UK-listed animal health company. It is both a commercial partner and a strategic peer shaping the go-to-market model for Orthros's veterinary pipeline.

Others

• QVQ: QVQ is a Dutch VHH antibody discovery and development company and a minority shareholder and core R&D partner of Orthros. It is a direct enabling technology partner and a key supplier of antibody selection capabilities underpinning Orthros's pipeline.

Emerging players

• Hy2Care: Hy2Care is a University of Twente spin-off co-founded by Orthros's CSO Marcel Karperien, developing injectable hydrogels for cartilage repair in osteoarthritis. It is an adjacent emerging player in OA, sharing scientific origins and therapeutic focus with Orthros.
• Regenesance: Regenesane was a prior biotech venture led by Orthros's CEO Robert Jan Lamers, focused on regenerative medicine. It is a relevant peer to understand Lamers's prior operating track record in musculoskeletal/regenerative biotech.
• LipoCoat: LipoCoat is another University of Twente spin-off co-founded by Orthros's CSO, focused on biomaterial coatings for medical devices. It shares academic and entrepreneurial DNA with Orthros and is part of the same Twente life-sciences cluster.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orthros-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orthros Medical